Ovid Therapeutics Inc. (OVID)

Market Cap	74.56M
Revenue (ttm)	631,695
Net Income (ttm)	-32.50M
Shares Out	71.01M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,608
Open	1.060
Previous Close	1.060
Day's Range	1.020 - 1.065
52-Week Range	0.680 - 4.100
Beta	0.41
Analysts	Strong Buy
Price Target	4.04 (+284.76%)
Earnings Date	Nov 12, 2024

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2017
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: OVID
• Website: https://www.ovidrx.com

Financial Performance

In 2023, Ovid Therapeutics's revenue was $391,695, a decrease of -73.93% compared to the previous year's $1.50 million. Losses were -$52.34 million, -3.38% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price forecast is $4.04, which is an increase of 284.76% from the latest price.

Price Target

$4.04

(284.76% upside)

Analyst Consensus: Strong Buy